(Reuters) – French drugmaker Valneva said on Monday that the application for its vaccine candidate against mosquito-borne viral disease chikungunya was accepted by the European Medicines Agency (EMA) which would now examine the drug in a fast-track procedure.
The EMA “has determined that all essential regulatory elements required for scientific assessment were included in the application,” Valneva said in a statement.
Accelerated assessment reduces the timeframe the EMA review to 150 days from 210 days, Valneva said.
(Reporting by Olivier Sorgho)
